2026年7月28日，美因基因有限公司（股票代码：06667）发布公告称，于香港联合交易所回购股份10.82万股，占该公司于回购前已发行股本约0.0484%，每股回购价格介乎7.08港元至7.10港元，涉资共计约76.61万港元。回购完成后，公司已发行股本从原有的223,640,400股减少至223,532,200股，库藏股从659,800股增至768,000股，合计股份总数保持在224,300,200股。
公告显示，本次股份购回依照公司于2026年5月21日通过的购回授权进行，授权可购回股份总数为22,430,020股。截至本次回购后，公司已在交易所购回768,000股，占购回授权决议通过当日已发行股本约0.3424%。公司确认已遵守香港联交所证券上市规则以及相关法律法规。公告由董事姜晶签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.